Edition:
India

Sosei Group Corp (4565.T)

4565.T on Tokyo Stock Exchange

2,609JPY
19 Jul 2019
Change (% chg)

¥29 (+1.12%)
Prev Close
¥2,580
Open
¥2,614
Day's High
¥2,657
Day's Low
¥2,593
Volume
3,288,600
Avg. Vol
4,430,741
52-wk High
¥2,773
52-wk Low
¥748

Latest Key Developments (Source: Significant Developments)

Sosei Heptares Says Marketing Application For Asthma Therapy Has Been Filed With EMA
Friday, 24 May 2019 

May 24 (Reuters) - Sosei Group Corp <4565.T>::SOSEI HEPTARES NOTES THAT A VALID MARKETING AUTHORIZATION APPLICATION FOR QVM149, A POTENTIAL NEW INHALED COMBINATION THERAPY FOR ASTHMA, HAS BEEN FILED WITH EUROPEAN MEDICINES AGENCY.MAA FILING HAS TRIGGERED A $2.5 MILLION PAYMENT TO SOSEI HEPTARES FROM NOVARTIS.  Full Article

Sosei Group Says Sosei Heptares To Get US$15 Mln Milestone Payment From Astrazeneca
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Sosei Group Corp <4565.T>::NOTIFIED BY ASTRAZENECA IT REACHED CLINICAL DEVELOPMENT MILESTONE WITH PARTNERED NEXT GENERATION IMMUNO-ONCOLOGY CANDIDATE AZD4635.SOSEI HEPTARES TO GET US$15 MILLION MILESTONE PAYMENT FROM ASTRAZENECA WITH FIRST PARTNERED PROGRAM MOVING TOWARDS PHASE 2.  Full Article

Sosei Group regains worldwide rights from Teva to develop and commercialize novel small molecule CGRP antagonists for migraine and other severe headaches
Tuesday, 13 Mar 2018 

March 13 (Reuters) - Sosei Group Corp <4565.T>:Says co has regained worldwide rights from Teva Pharmaceutical Industries Ltd., to develop and commercialize lead candidate HTL0022562 and other novel small molecule CGRP antagonists for the treatment of migraine and other severe headaches.  Full Article

Sosei Group says new share prices
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Sosei Group Corp <4565.T>:Says it will issue new shares of its common stock via overseas offering, with the issue price of 10,800 yen per share (22.36 billion yen in total) and paid-in price of 10,283.55 yen per share (21.29 billion yen in total).Says payment date on Nov. 27.Previous news was disclosed on Nov. 10.  Full Article

Sosei Group to issue 2.1 mln new shares
Friday, 10 Nov 2017 

Nov 10(Reuters) - Sosei Group Corp <4565.T>:Says it plans to issue 2.1 million new shares through overseas offering .Proceeds to be mainly used for drug discovery and research and development related fund .  Full Article

Sosei Group to advance clinical development in Japan of HTL0018318 in patients with Dementia with Lewy Bodies (DLB)
Thursday, 9 Nov 2017 

Nov 9(Reuters) - Sosei Group Corp <4565.T>:Says it gains a licence to develop and commercialise HTL0018318, a novel muscarinic M1 receptor agonist, in Japan as a potential new treatment for patients with dementia with Lewy bodies (DLB).Says it will undertake a Phase 2 proof-of-concept monotherapy study, expected to begin in Japan in 2018 .  Full Article

Mina Therapeutics partners with Boehringer Ingelheim
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Sosei Group Corp <4565.T>:Strategic minority investment company Mina Therapeutics enters into collaboration and licensing agreement with Boehringer Ingelheim.Under agreement, Mina to receive an upfront payment, funding and payments of up to EUR 307 million​.Mina is also entitled to double-digit royalties on sales of selected products resulting from partnership​.No further financial details were disclosed​.  Full Article

Sosei Group unit says first subject dosed in Phase1 clinical study of novel selective muscarinic M4 agonist in development to treat major symptoms of Alzheimer's disease
Friday, 1 Sep 2017 

Sept 1 (Reuters) - Sosei Group Corp <4565.T>:Says co's unit Heptares Therapeutics and Allergan announced that the first healthy subject has been dosed with the first-in-class, selective muscarinic M4 receptor agonist HTL0016878 in a Phase 1 clinical study .Says unit will receive $15 million milestone payment under a global R&D and commercialisation partnership announced in April 2016.  Full Article

Sosei Group to sell Chiba-based pharmaceutical unit for $3.5 mln
Friday, 4 Aug 2017 

Aug 4 (Reuters) - Sosei Group Corp <4565.T>:* Says it will sell Chiba-based pharmaceutical unit to Formosa Pharmaceuticals, Inc., which is unit of Formosa.* Says it will complete the transaction on Aug. 10 .  Full Article